These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 28857847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S.
    Clin Calcium; 2012 Mar 15; 22(3):315-20. PubMed ID: 22370297
    [Abstract] [Full Text] [Related]

  • 4. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N, Okamoto M, Tsuji S, Endo Y, Takatani A, Shimizu T, Umeda M, Fukui S, Sumiyoshi R, Igawa T, Koga T, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Nakamura H, Origuchi T, Eguchi K, Ueki Y, Kawakami A.
    J Bone Miner Metab; 2019 May 15; 37(3):554-562. PubMed ID: 30187273
    [Abstract] [Full Text] [Related]

  • 5. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec 15; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 6. Glucocorticoid induced osteoporosis.
    Hu K, Adachi JD.
    Expert Rev Endocrinol Metab; 2019 Jul 15; 14(4):259-266. PubMed ID: 31094232
    [Abstract] [Full Text] [Related]

  • 7. [Glucocorticoid-induced osteoporosis-Focus treatment (part 2)].
    Oelzner P, Eidner T, Pfeil A.
    Z Rheumatol; 2022 Mar 15; 81(2):125-133. PubMed ID: 35006381
    [Abstract] [Full Text] [Related]

  • 8. [Therapy of glucocorticoid induced osteoporosis].
    Arazzi M, Di Fulvio G, Di Pietro LO, Grabocka X, Longo MO, Micioni G, Pezzutto A, Piscitani L, Schiazza A, Silvestri S, Vigilante G, Amoroso L, Bonomini M.
    G Ital Nefrol; 2017 Dec 05; 34(Nov-Dec):. PubMed ID: 29207221
    [Abstract] [Full Text] [Related]

  • 9. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T.
    Arthritis Rheumatol; 2017 Aug 05; 69(8):1521-1537. PubMed ID: 28585373
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM.
    Osteoporos Int; 2016 Jun 05; 27(6):1989-98. PubMed ID: 26782683
    [Abstract] [Full Text] [Related]

  • 11. Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment.
    Hirooka Y, Nozaki Y, Okuda S, Sugiyama M, Kinoshita K, Funauchi M, Matsumura I.
    Front Endocrinol (Lausanne); 2021 Jun 05; 12():753185. PubMed ID: 34646240
    [Abstract] [Full Text] [Related]

  • 12. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov 05; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 13. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 05; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 14. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN.
    N Engl J Med; 2007 Nov 15; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract] [Full Text] [Related]

  • 15. New therapeutic targets for osteoporosis.
    Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG.
    Maturitas; 2019 Feb 15; 120():1-6. PubMed ID: 30583758
    [Abstract] [Full Text] [Related]

  • 16. Update on Glucocorticoid Induced Osteoporosis.
    Cho SK, Sung YK.
    Endocrinol Metab (Seoul); 2021 Jun 15; 36(3):536-543. PubMed ID: 34107602
    [Abstract] [Full Text] [Related]

  • 17. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF.
    Lancet Diabetes Endocrinol; 2018 Jun 15; 6(6):445-454. PubMed ID: 29631782
    [Abstract] [Full Text] [Related]

  • 18. Glucocorticoid-induced osteoporosis and osteonecrosis.
    Weinstein RS.
    Endocrinol Metab Clin North Am; 2012 Sep 15; 41(3):595-611. PubMed ID: 22877431
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
    Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q.
    Arch Osteoporos; 2024 Sep 23; 19(1):89. PubMed ID: 39312040
    [Abstract] [Full Text] [Related]

  • 20. Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study.
    Kawabata A, Yoshii T, Hirai T, Ushio S, Kaito T, Yamashita T, Fujiwara H, Nagamoto Y, Matsuoka Y, Suzuki H, Nishimura H, Terai H, Tamai K, Tagami A, Yamada S, Adachi S, Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Harimaya K, Kawaguchi K, Yokoyama N, Oishi H, Doi T, Kimura A, Inoue H, Inoue G, Miyagi M, Saito W, Nakano A, Sakai D, Nukaga T, Ikegami S, Shimizu M, Futatsugi T, Ohtori S, Furuya T, Orita S, Imagama S, Ando K, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Oshima M, Takahata M, Iwata A, Endo H, Abe T, Tsukanishi T, Nakanishi K, Watanabe K, Hikata T, Suzuki S, Isogai N, Okada E, Funao H, Ueda S, Shiono Y, Nojiri K, Hosogane N, Ishii K.
    BMC Musculoskelet Disord; 2020 Jul 01; 21(1):420. PubMed ID: 32611386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.